LifeAssays® AB

LifeAssays® –Strategically placed in the IDEON Science Park

LifeAssays® established 2000Localised in Lund, IDEON Science ParkMagnasence, 100% owned subsidiary in Finland purchased 2015Subsidiary in China 2017, 61% owned by LifeAssaysPublicly traded, listed onNGM in Stockholm

We move diagnostics closer to the patient

2

LifeAssays® and MST –a unique combination of strengths to conquernew market segments in veterinary diagnostics

The VetReader and MagniaReader Vet movesthe diagnostic testing fromthe service laboratory to the Veterinary clinic

The Quantitative Disposable Analyser (QDA) moves the diagnostic testing from the clinic to the veterinarians/ doctors pocket

3

Sales and MarketingBusiness developmentElectronics and SoftwareChemistry/immunologyAssays developmentProduction of reagents in-house, instruments out-sourced

Focus on veterinary diagnostics in Lund and platform development and human diagnostics in Helsinki

Electronics & SoftwareProject Mgm.Development and Production out sourcedFocused on the Quantitative Disposable Analyser, QDA

The Lund facilityVeterinary

The Helsinki facilityHuman and platform dev.

4

The veterinary diagnostic markets shows highest growth in pet segment and more specifically in testing of dogsThe veterinary diagnostic market

More than 4 bUSD/year in total value

Of which more than2 bUSD/year for pets

Of which more than1 bUSD/year value for dogs alone

Point of Care (POC) system for veterinary diagnostic applications, marketing products:§ Canine CRP (VetReader)§ Canine hs-CRP (VetReader)§ Feline SAA (VetReader) § Equine SAA (MagniaReader)

Point of Need (PON) platform§ QDA with integrated sample

preparation§ Stand alone Sample prep

5

The human diagnostic markets is expecting rapid growth in the home testing market the coming10 years

Point of Care platform,the MagniaReader§ Human CRP

Point of Need platform§ QDA platform § QDA platform with integrated

sample preparation§ Stand alone sample prep.

6

The human diagnostic market

Total value of close to 90 bUSD/year in 2023

PoC segment close to 40 bUSD

Home testing outside blood glucose§ Treatment monitoring§ Follow disease markers§ Assist e-doctors§ Fertility/infertility

Development of products andmarkets, examples

Focused development of QDA in Finland§ 2017 took the project from idea to a functional model§ Added a sample preparation unit for ”ease of use” and

improved performance.§ 2018 - the year of validation and industrialisation.§ 2019 - first products will be launched in the veterinary market

Addition of inflammation test for cat on VetReader, strengthen our position in the market§ Strengthen our position in the market, high margin test.§ 2018 - additional tests for dog and cat

New test system for equine SAA. § MagniaReader Vet with inflammation test for horse§ 2018 - additional equine markers

Production of VetReader and MagniaReader instruments outsourced, reagent development and production under evaluation.

7

Successful focus on selected markets during 2017

Nordic1 100 Clinics700 target clinics240 VetReaders today

Sweden900 000 dogs1 500 000 cats300 clinics

USA25 000 Clinics70 000 Practitioners90 M dogs, 95 M cats

China12 000 Clinics in total600 High end clinics6 000 Mid level clinics5 400 Low end clinics

Continued growth in sales of feline SAA (fSAA).

§ Higher margin than the canine CRP test

§ Makes VetReader considerably more competitive.

Tremendous response in the Nordic market for eSAA. Next step is USA and Germany

§ High margin test

VetReader and MagniaReader on the US market

§ The combination dog/cat and horse has given new possibilities on the US market.

§ Letter of Intent with Partner in place – ClienTrax..

Established subsidiary in China (Qingdao) –Qingdao Lai Fu Ai Sheng Medical Technology

8

LifeAssays® AB –The Quantitative Disposable Analyzer, QDA

For use in ultimate veterinary

point-of-care situations

Applicable both in professional

and home testing in human

medicine

Rapid – test results in

5 minutes

Easy – integrated

sample handling unit

for maximum

performance with

minimum hands on

Accurate – Excellent

correlation with

MagniaReader POC

system

Veterinary applications –

LifeAssays

Human medicine

applications – Partners

through for example out

licensing or selling the

technology

LifeAssays® QDA adding value to the company –

unique product platform in rapidly growing home testing

(OTC) market

Unique disposable

quantitative test under

development, Quantitative

Disposable Analyser (QDA)

QDA - Rapid, Easy

and Accurate

Applications in

veterinary as well as

human medicine

QDA

10

LifeAssays® QDA adding value to the company –unique product platform in rapidly growing home testing (OTC) marketGlobal blood testing market is anticipated to reach USD 62.9 billion by 2024, according to a new report by Grand View Research, Inc.

Growing adoption of testing and screening methodologies that enhance near patient diagnosis through enhanced blood testing that reduce diagnostic turnaround times and lower hospitals stay durations is a major factor expected to provide lucrative growth in demand for the market. (Grand view Research)

… moreover, the home end user segment is anticipated to exhibit the highest growth, with a CAGR of 9.7% during the forecast period.This is owing to increase in adoption of at-home point of care diagnostics and rapid launch of innovative and advanced portable devices. Over-the-counter testing kits segment

is projected to grow at a CAGR of 104%during analysis period, i.e. 2015 to 2022.(Med Device on line)

….Glycated hemoglobin (aka A1C testing) is anticipated to witness significant growth through to 2024 owing to developments in this segment for assessment of glucose levels using this method. Additionally, as this test does not require fasting and sample can be drawn for the test at any time of the day, it is relatively more convenient for patients thereby resulting in progressively growing prescription rates from clinicians and pathologists.(Grand view Research)

11

LifeAssays® QDA –comparable performance to

Correlation between measured value (QDA)and known sample value.§ Y = 0,992x§ R(2) = 0,998

Interception = 0 Human CRP used, triplicates

12

LifeAssays® AB – share issuing on 22,2 + 4 MSEK + subscribtion rights

LifeAssays® share issuing – secure product and market development

Extra ordinary Share holders meeting on May 4 for decision

22,2 + 4 MSEK + Subscription rights

100% guaranteed§ Board, Mgm and two biggest

shareholders – 36%

§ External guarantees – 64%

Subscription, 29 May to12 June

www.lifeassays.com

14

LifeAssays® share issuing – secure product and market development

Further strengthen the position in the Nordic countries Strengthen marketing and sales in China through subsidiary.Focus M&S efforts in USA and Germany through Partners.Strengthen product portfolio on VetReader and MagniaReader.Resource optimisation to lower costs and increase efficiency.Pave the way for out licensing and/or sales of rights to human application on the QDA to start this autumn.

15

www.lifeassays.com